Donor-derived Natural Killer Cell

Phase 2Biologic

FFederal Research Institute of Pediatric Hematology, Oncology and Immunology

Donor-derived Natural Killer Cell is one of 47 biologic programs targeting Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukemiaActive, not recruiting

LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Leukemia

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Phase 3

31 2

Fludara

Sanofi

Phase 3

22 3

Idamycin

Pfizer

Phase 3

10 4

Neoral

Novartis

Phase 3

9 5

Decadron

AAspen Global Incorporated

Phase 3

24 6

Neupogen

EEastern Cooperative Oncology Group

Phase 3

15 7

Oncovin

EEastern Cooperative Oncology Group

Phase 3

15 8

Busulfex

Akero Therapeutics

Phase 3

13 9

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

12 10

Mesnex

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Leukemia

NCT07256210

Clinical

Trials by Indication[1]

Leukemia1 trial

Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation

Recruiting·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 2·NCT07256210·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Donor-derived Natural Killer Cell. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Donor-derived Natural Killer Cell compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Donor-derived Natural Killer Cell. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Federal Research Institute of Pediatric Hematology, Oncology and Immunology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: FFederal Research Institute of Pediatric Hematology, Oncology and Immunology

Donor-derived Natural Killer Cell

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Leukemia1 trial

References

Drug Info

Quick Facts

Related News